![]() The core of the bioequivalence concept is an absence of a significant difference, which is considered to be less than 20% by the FDA. ![]() The FDA uses an average bioequivalence approach involving a comparison of means when it is determining a product’s bioequivalence. Laws Concerning Bioequivalence and NTI Drugs Such drugs have less than a twofold difference in the minimum toxic concentration and minimum effective concentration in the blood or are those drug product formulations that exhibit limited or erratic absorption, formulation-dependent bioavailability, and wide intrapatient pharmacokinetic variability that requires blood-level monitoring.” 2 As defined by the Therapeutic Products Directorate of Health Canada, an NTR drug is a drug wherein the ratio of the lowest concentration at which clinical toxicity occurs, to the median concentration providing a therapeutic effect, is less than or equal to two. ![]() The North Carolina Board of Pharmacy defines an NTI drug as “those pharmaceuticals having a narrowly defined range between risk and benefit. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |